Clinical Nutrition, Journal Year: 2025, Volume and Issue: 48, P. 6 - 15
Published: March 6, 2025
Language: Английский
Drug Discovery Today, Journal Year: 2024, Volume and Issue: 29(3), P. 103910 - 103910
Published: Feb. 1, 2024
Language: Английский
Citations
66
The Lancet Diabetes & Endocrinology, Journal Year: 2024, Volume and Issue: unknown
Published: Dec. 1, 2024
Language: Английский
Citations
29
Nature Reviews Disease Primers, Journal Year: 2025, Volume and Issue: 11(1)
Published: March 6, 2025
Language: Английский
Citations
12
Journal of Hepatology, Journal Year: 2025, Volume and Issue: unknown
Published: Jan. 1, 2025
Language: Английский
Citations
8
Journal of Hepatology, Journal Year: 2025, Volume and Issue: unknown
Published: March 1, 2025
The liver acts as a central metabolic hub, integrating signals from the gastrointestinal tract and adipose tissue to regulate carbohydrate, lipid, amino acid metabolism. Gut-derived metabolites, such acetate ethanol non-esterified fatty acids white (WAT), influence hepatic processes, which rely on mitochondrial function maintain systemic energy balance. Metabolic dysregulation obesity, insulin resistance, type 2 diabetes disrupt these pathways, leading dysfunction-associated steatotic disease (MASLD) steatohepatitis (MASH). This review explores fluxes within gut-adipose tissue-liver axis, focusing pivotal role of de novo lipogenesis (DNL), dietary substrates like glucose fructose, changes in during MASLD progression. It highlights contributions resistance impaired dynamics lipid accumulation. Further understanding how interplay between substrate flux gastro-intestinal integrates with intersects structural functional alterations mitochondria will be important identify novel therapeutic targets advance treatment MASH.
Language: Английский
Citations
4
Lipids in Health and Disease, Journal Year: 2024, Volume and Issue: 23(1)
Published: April 2, 2024
Abstract Metabolic dysfunction-associated steatotic liver disease (MASLD) is the leading cause of chronic that affects over 30% world’s population. For decades, heterogeneity non-alcoholic fatty (NAFLD) has impeded our understanding mechanism and development effective medications. However, a recent change in nomenclature from NAFLD to MASLD emphasizes critical role systemic metabolic dysfunction pathophysiology this therefore promotes progress pharmaceutical treatment MASLD. In review, we focus on underlying abnormality hepatic lipid metabolism patients with MASLD, summarize latest therapeutic medications target disorders.
Language: Английский
Citations
14
Diabetes Research and Clinical Practice, Journal Year: 2024, Volume and Issue: 217, P. 111846 - 111846
Published: Sept. 6, 2024
Language: Английский
Citations
13
Frontiers in Immunology, Journal Year: 2024, Volume and Issue: 15
Published: Jan. 17, 2024
Metabolic dysfunction-associated steatohepatitis (MASH) is the replacement term for what used to be called nonalcoholic (NASH). It characterized by inflammation and injury of liver in presence cardiometabolic risk factors may eventually result development hepatocellular carcinoma (HCC), most common form primary cancer. Several pathogenic mechanisms are involved transition from MASH HCC, encompassing metabolic injury, inflammation, immune dysregulation fibrosis. In this context, Gas6 (Growth Arrest-Specific 6) TAM (Tyro3, Axl, MerTK) receptors play important roles. The Gas6/TAM family modulation lipid metabolism, fibrosis, tumor progression metastasis, processes which an role pathophysiology acute chronic diseases. review, we discuss MASH-associated HCC potential involvement system disease progression. addition, since therapeutic strategies limited, also speculate regarding possible future treatments involving targeting or receptors.
Language: Английский
Citations
10
Trends in Pharmacological Sciences, Journal Year: 2024, Volume and Issue: 45(4), P. 319 - 334
Published: March 12, 2024
Steatotic liver diseases (SLDs) affect one-third of the population, but pathogenesis underlying these is not well understood, limiting available treatments. A common factor in SLDs increased hepatic mitochondrial reductive stress, which occurs as a result excessive lipid and alcohol metabolism. Recent research has also shown that genetic risk factors contribute to this stress. This review aims explore how increase stress it disrupts metabolism, leading SLDs. Additionally, will discuss latest clinical studies on pharmaceutical treatments for SLDs, specifically peroxisome proliferator-activated receptor gamma (PPAR-γ) agonists, thyroid hormone (THR) acetyl-CoA carboxylase (ACC) inhibitors, uncouplers. These have effect decreasing been largely overlooked.
Language: Английский
Citations
10
Clinical and Molecular Hepatology, Journal Year: 2024, Volume and Issue: unknown
Published: Aug. 5, 2024
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a complex multifactorial and becoming the leading cause of liver-related morbidity mortality. MASLD spans from isolated steatosis to metabolic steatohepatitis (MASH), that may progress cirrhosis hepatocellular carcinoma (HCC). Genetic, metabolic, environmental factors strongly contribute heterogeneity MASLD. Lifestyle intervention weight loss represent viable treatment for Moreover, Resmetirom, thyroid hormone beta receptor agonist, has recently been approved treatment. However, most individuals treated did not respond this therapeutic suggesting need more tailored approach treat Oligonucleotide-based therapies, namely small-interfering RNA (siRNA) antisense oligonucleotide (ASO), have developed tackle by reducing expression genes influencing MASH progression, such as PNPLA3 HSD17B13. Here, we review latest made in synthesis development oligonucleotide-based agents targeting genetic determinants MASH.
Language: Английский
Citations
10